SB Medical Limited Small abridged accounts

SB MEDICAL LIMITED - Company Information

false false false false false false false false false true false false false false false false false No description of principal activity 2017-04-01 Sage Accounts Production Advanced 2017 Update 2 - FRS xbrli:pure xbrli:shares iso4217:GBP 06929389 2017-04-01 2018-03-31 06929389 2018-03-31 06929389 2017-03-31 06929389 bus:Director1 2017-04-01 2018-03-31 06929389 bus:Director2 2017-04-01 2018-03-31 06929389 core:WithinOneYear 2018-03-31 06929389 core:WithinOneYear 2017-03-31 06929389 core:ShareCapital 2018-03-31 06929389 core:ShareCapital 2017-03-31 06929389 core:RetainedEarningsAccumulatedLosses 2018-03-31 06929389 core:RetainedEarningsAccumulatedLosses 2017-03-31 06929389 core:CostValuation core:Non-currentFinancialInstruments 2018-03-31 06929389 core:Non-currentFinancialInstruments 2018-03-31 06929389 bus:FRS102 2017-04-01 2018-03-31 06929389 bus:AuditExempt-NoAccountantsReport 2017-04-01 2018-03-31 06929389 bus:AbridgedAccounts 2017-04-01 2018-03-31 06929389 bus:SmallCompaniesRegimeForAccounts 2017-04-01 2018-03-31 06929389 bus:PrivateLimitedCompanyLtd 2017-04-01 2018-03-31

Statement of Consent to Prepare Abridged Financial Statements

All of the members of SB Medical Limited have consented to the preparation of the abridged statement of income and retained earnings and the abridged statement of financial position for the year ending 31 March 2018 in accordance with Section 444(2A) of the Companies Act 2006.

COMPANY REGISTRATION NUMBER: 06929389

SB Medical Limited

Filleted Unaudited Abridged Financial Statements

31 March 2018

SB Medical Limited

Abridged Financial Statements

Year ended 31 March 2018

Contents	Page

Abridged statement of financial position	1

Notes to the abridged financial statements	3

SB Medical Limited

Abridged Statement of Financial Position

31 March 2018

	2018		2017
Note	£	£	£

Fixed assets

Investments	4		280,077	280,077

Current assets

Debtors	184,000	5,000
Cash at bank and in hand	25,747	193,630
	---------	---------
	209,747	198,630

Creditors: amounts falling due within one year	8,099		11,343
	---------		---------
Net current assets		201,648	187,287
		---------	---------
Total assets less current liabilities		481,725	467,364
		---------	---------
Net assets		481,725	467,364
		---------	---------

Capital and reserves

Called up share capital	1,000	1,000
Profit and loss account	480,725	466,364
	---------	---------
Members funds	481,725	467,364
	---------	---------

These abridged financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the abridged statement of income and retained earnings has not been delivered.

For the year ending 31 March 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its abridged financial statements for the year in question in accordance with section 476 ;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of abridged financial statements .

SB Medical Limited

Abridged Statement of Financial Position (continued)

31 March 2018

These abridged financial statements were approved by the board of directors and authorised for issue on 14 November 2018 , and are signed on behalf of the board by:

Dr S Bansal	Dr A Agarwal
Director	Director

Company registration number: 06929389

SB Medical Limited

Notes to the Abridged Financial Statements

Year ended 31 March 2018

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 90 Copse Hill, Harlow, Essex, CM19 4PP.

2. Statement of compliance

These abridged financial statements have been prepared in compliance with the provisions of FRS 102 Section 1A, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

Freehold property is not depreciated. The directors are of the opinion that the value exceeds the stated cost.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Investments

Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.

Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

Investments in associates

Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.

Investments in joint ventures

Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

4. Investments

	£
Cost
At 1 April 2017 and 31 March 2018	280,077
	---------
Impairment
At 1 April 2017 and 31 March 2018	–
	---------
Carrying amount
At 31 March 2018	280,077
	---------

5. Related party transactions

No transactions with related parties were undertaken such as are required to be disclosed under Financial Reporting Standard for smaller entities.